Combination Treatment With Everolimus, Letrozole and Trastuzumab in Hormone Receptor and HER2/Neu-Positive Patients With Advanced Metastatic Breast Cancer and Other Solid Tumors: Evaluating Synergy and Overcoming Resistance
Status: Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 08 Nov 2019
Price : $35 *
At a glance
- Drugs Everolimus (Primary) ; Letrozole (Primary) ; Trastuzumab (Primary)
- Indications Advanced breast cancer; Solid tumours
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- 05 Nov 2019 Planned End Date changed from 31 Jul 2019 to 31 Jul 2021.
- 05 Nov 2019 Planned primary completion date changed from 31 Jul 2019 to 31 Jul 2021.
- 15 May 2019 Planned End Date changed from 1 Jul 2020 to 31 Jul 2019.